Brief Introduction about Follicular Lymphoma :
A lymphoma is a form of white blood cell malignancy that affects lymphocytes. The lymphatic system, which comprises the bone marrow, spleen, thymus, and lymph nodes, allows lymphocytes to circulate throughout the body. The lymphatic system’s organs and channels work together to make and store cells that fight infection.
Various Treatment Options Available For Follicular Lymphoma :
Depending on the severity of accompanying symptoms and the rate of cancer progression, there are a variety of Follicular Lymphoma Treatment options available. If patients have no or few symptoms, doctors may advise against treating the disease straight soon, a strategy is known as active surveillance (“watch and wait”). Patients who are handled with an active surveillance method have survival outcomes that are comparable to those who are treated early in the course of their disease, according to studies. Patients’ overall health and disease are evaluated using this technique, which includes regular checkup visits and other evaluations such as laboratory and imaging examinations. If the patient develops lymphoma-related symptoms or there is evidence that the disease is progressing based on tests during follow-up visits, active therapy is started.
Radiation and chemotherapy are generally very effective in treating Follicular Lymphoma. In some patients with mild illness, radiation alone can achieve long-term remission. Physicians may employ one or more chemotherapeutic medications, as well as the monoclonal antibody rituximab (Rituxan), alone or in combination with other therapies, in more advanced stages.
By targeting specific markers found on B-cells and engaging immune cells to assist tumor death, monoclonal antibodies can operate more directly than chemotherapeutic drugs, potentially increasing treatment response.
Common combination regimens include:
- R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone)
- R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
- R-Bendamustine (rituximab and bendamustine)
For patients with no indications of lymphoma, certain monoclonal antibodies can be maintained as maintenance therapy for up to two years to sustain remission. Another therapeutic option for FL is radioimmunotherapy (RIT), which involves the use of a radioactive particle called yttrium-90 ibritumomab tiuxetan (Zevalin) that is linked to an antibody that targets cancer cells.